Search

Your search keyword '"de Vries YA"' showing total 3 results
Start Over Author "de Vries YA" Topic attention deficit disorder with hyperactivity
3 results on '"de Vries YA"'

1. Editorial Perspective: Are treatments for childhood mental disorders helpful in the long run? An overview of systematic reviews.

Author

Roest AM, de Vries YA, Wienen AW, and de Jonge P

Subjects
Child, Humans, Adolescent, Systematic Reviews as Topic, Anxiety Disorders therapy, Anxiety Disorders epidemiology, Comorbidity, Mental Disorders therapy, Mental Disorders epidemiology, Attention Deficit Disorder with Hyperactivity epidemiology, Conduct Disorder
Abstract

Mental disorders may have severe consequences for individuals across their entire lifespan, especially when they start in childhood. Effective treatments (both psychosocial and pharmacological) exist for the short-term treatment of common mental disorders in young people. These could, at least theoretically, prevent future problems, including recurrence of the disorder, development of comorbidity, or problems in functioning. However, little is known about the actual effects of these treatments in the long run. In the current editorial perspective, we consider the available evidence for the long-term (i.e., ≥2 years) effectiveness and safety of treatments for attention deficit hyperactivity disorder, behavior disorders, and anxiety and depressive disorders for children between 6 and 12 years old. After providing an overview of the literature, we reflect on two key issues, namely, methodological difficulties in establishing long-term treatment effects, and the risk-benefit ratio of treatments for common childhood mental disorders. In addition, we discuss future research possibilities, clinical implications, and other approaches, specifically whole-of-society-actions that could potentially reduce the burden of common childhood mental disorders., (© 2022 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.)

Published
2023
Full Text
View/download PDF

2. Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis.

Author

Pittelkow MM, de Vries YA, Monden R, Bastiaansen JA, and van Ravenzwaaij D

Subjects
Humans, Bayes Theorem, Psychotropic Drugs therapeutic use, Antidepressive Agents therapeutic use, Antipsychotic Agents therapeutic use, Attention Deficit Disorder with Hyperactivity drug therapy
Abstract

Approval and prescription of psychotropic drugs should be informed by the strength of evidence for efficacy. Using a Bayesian framework, we examined (1) whether psychotropic drugs are supported by substantial evidence (at the time of approval by the Food and Drug Administration), and (2) whether there are systematic differences across drug groups. Data from short-term, placebo-controlled phase II/III clinical trials for 15 antipsychotics, 16 antidepressants for depression, nine antidepressants for anxiety, and 20 drugs for attention deficit hyperactivity disorder (ADHD) were extracted from FDA reviews. Bayesian model-averaged meta-analysis was performed and strength of evidence was quantified (i.e. BF BMA ). Strength of evidence and trialling varied between drugs. Median evidential strength was extreme for ADHD medication ( BF BMA = 1820.4), moderate for antipsychotics ( BF BMA = 365.4), and considerably lower and more frequently classified as weak or moderate for antidepressants for depression ( BF BMA = 94.2) and anxiety ( BF BMA = 49.8). Varying median effect sizes ( ES schizophrenia = 0.45, ES depression = 0.30, ES anxiety = 0.37, ES ADHD = 0.72), sample sizes ( N schizophrenia = 324, N depression = 218, N anxiety = 254, N ADHD = 189.5), and numbers of trials ( k schizophrenia = 3, k depression = 5.5, k anxiety = 3, k ADHD = 2) might account for differences. Although most drugs were supported by strong evidence at the time of approval, some only had moderate or ambiguous evidence. These results show the need for more systematic quantification and classification of statistical evidence for psychotropic drugs. Evidential strength should be communicated transparently and clearly towards clinical decision makers.

Published
2021
Full Text
View/download PDF

3. A Prescription Trend Analysis of Methylphenidate: Relation to Study Reports on Efficacy.

Author

Sluiter MN, de Vries YA, Koning LG, Hak E, Bos JHJ, Schuiling-Veninga CCM, Batstra L, Doornenbal JM, and de Jonge P

Subjects
Adolescent, Attention Deficit Disorder with Hyperactivity epidemiology, Central Nervous System Stimulants therapeutic use, Child, Child, Preschool, Dose-Response Relationship, Drug, Female, Humans, Male, Methylphenidate therapeutic use, Netherlands epidemiology, Practice Guidelines as Topic, Practice Patterns, Physicians' statistics & numerical data, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants administration & dosage, Drug Utilization statistics & numerical data, Methylphenidate administration & dosage, Prescriptions statistics & numerical data
Abstract

Use of methylphenidate in children has increased substantially, despite conflicting evidence regarding efficacy. In this study, prescription data were analyzed in relation to the publication of new evidence regarding efficacy. Incidence rates and prescribed doses of methylphenidate increased, with a decline during the last few years. Duration of use is still increasing. In half of the cases, starting dosages are higher than recommended in guidelines. There was little evidence that publication of new evidence directly influenced the use of methylphenidate. Recent and critical study findings should receive more attention to contribute to the development and use of treatment guidelines for ADHD and evidence-based methylphenidate use.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results